In CRC, analysis of the molecular features of individual CTCs has revealed significant heterogeneity in the presence of EGFR mutations and other genetic mutations associated with EGFR inhibition (such as KRAS and PIK3CA mutations) among patients and between patients, which explains the different response rates to EGFR-targeted therapy (95). This evidence concerns the gene EGFR and colorectal carcinoma.